Munguva pfupi yapfuura, China National Medical Products Administration (NMPA) yakabvumidza chiratidzo chitsva cheBireociclib, mushonga mutsva weClass 1 wakagadzirwa wega neXuanzhu Biopharmaceutical. Chiratidzo chitsva ichi ndechekushandiswa pamwe chete nearomatase inhibitor senzira yekutanga yekurapa endocrine kune varwere vane HR+/HER2- advanced cancer yemazamu. Kubvumidzwa uku kunoratidza Bireociclib semushonga wekutanga uye wega mukirasi yayo muChina wekuvhara nzira yese yekurapwa kweHR+/HER2- advanced cancer yemazamu—kusanganisira nzira yekutanga, nzira yechipiri, uye nzira yekupedzisira—uchipa sarudzo itsva yekurapa kune varwere pasi rese.
Kana iwe kana vadikanwi vako muchitsvaga nzira dziri nani dzekurapa kenza yemazamu, ndapota inzwa wakasununguka kubata International Department of Beijing South Region Oncology Hospital:
- Nhare: 400-880-3716
- WeChat: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
—
**Kubva paMutsetse Wechipiri kuenda paMutsetse Wekutanga: Kubudirira kwe"Kosi Yakazara" yeBireociclib**
Bireociclib mushonga mutsva weCDK2/4/6 inhibitor. Yakambobvumidzwa kushandiswa pamwe chete nefulvestrant yekurapa kenza yemazamu yakura iyo yakaramba ichikura mushure mekurapwa kweendocrine, pamwe nekurapwa kwevarwere vane chirwere chisingashande. Kubvumidzwa kwechiratidzo ichi chitsva kunosimudzira kushandiswa kwayo kusvika pakurapwa kweendocrine kwekutanga, zvichinyatsoita kuti ifukidzwe zvizere kubva pakurapwa kwekutanga kusvika pakurapwa kwekupedzisira.
Kubvumidzwa uku kwakavakirwa pamhedzisiro yekuongorora kwechinguvana yeBRIGHT-3. Chidzidzo ichi chakaratidza kuti medium progression-free survival (PFS) yeBireociclib plus AI group haisati yasvika, zvichiratidza kushanda kwenguva refu; kana tichienzanisa, PFS yeboka rekudzora yaive mwedzi 18.4. Zvinotonyanya kufadza, mwero wePFS wemakore maviri muboka reBireociclib wakapfuura 60%, uye mwero wemhinduro chaiyo (ORR) wakasvika 63.5%, zvichikwira kusvika 67.6% muvarwere vane maronda anoyerwa. Data iri rinoratidza kuti Bireociclib parizvino inoratidza kushanda kwepamusoro pakati pemishonga yakafanana.
**Dhizaini Yakanyanya Kunaka: Kushanda Nekuchengetedza Uye Kuenzanisa Zvinhu Zvakasiyana-siyana**
Kusiyana kweBireociclib kuri mukushanda kwayo kwe multi-target synergistic. Semushonga mutsva weCDK2/4/6 inhibitor, haingodziviriri CDK4 neCDK6 chete asiwo inodzivira CDK2 neCDK9 panguva imwe chete.
- **Kunonoka Kurapwa Nemishonga:** Kushanda kweCDK2 ndeimwe yenzira huru dzekudzivirira CDK4/6 inhibitors. Nekudzivisa CDK2 panguva imwe chete, Bireociclib inogona kuvharira zvakanyanya nzira dzekupararira kwemasero egomarara, nokudaro ichinonotsa kutanga kwekurapwa kwemishonga kubva kunobva mushonga.
- **Kuderera kweToxicity:** Kuipa kweropa kwakadai se grade 3/4 neutropenia, inowanzoonekwa neCDK4/6 inhibitors yechinyakare, kunoderedzwa zvakanyanya nekurapwa kweBireociclib. Izvi zvinoreva kuti varwere vanogona kuwana kutsungirira kuri nani kurapwa, vachideredza kukanganiswa kwekurapwa nekuda kwemigumisiro, nokudaro vachivimbisa kuenderera mberi kwekushanda.
**Data Rinosimbisa Simba: Kubudirira Kwakazara kweBRIGHT Study Series**
Kubudirira kwakanaka kweBireociclib hakusi kwega asi kwakavakirwa pahwaro hwakasimba hwezvidzidzo zveBRIGHT:
- **Kuongorora kwakajeka-2 (Kurapa Kwemutsara Wechipiri):** Bireociclib pamwe chete nefulvestrant yakawana avhareji yePFS yemwedzi 17.5. Mukuenzanisa kusiri kwekutarisana, data iri ndiro rakanakisa.
- **Chidzidzo cheBRIGHT-1 (Later-Line Monotherapy):** Kune varwere vakarapwa zvakanyanya vasati varapwa, vakanyanya kuramba kurapwa, Bireociclib monotherapy yakakonzera avhareji yePFS yemwedzi gumi nerimwe uye avhareji yekurarama kwese (OS) yemwedzi makumi maviri nemapfumbamwe. Iyi zvakare ipfungwa yepamusoro-soro yepasi rose, ichiratidza kushanda kwayo kwakasimba muvarwere vakanyanya kuoma.
**Sei Uchifanira Kusarudza Dhipatimendi Repasi Pose reBeijing South Region Oncology Hospital?**
Dhipatimendi rePasirose reBeijing South Region Oncology Hospital rakatsaurira kubatanidza hunyanzvi hwepamusoro hwemishonga pasi rose nezviwanikwa zvepamusoro zvekurapa zveChina. Semushonga mutsva wakagadzirwa muChina, kubvumidzwa kweBireociclib hakungobatsiri varwere vemuno chete asiwo kunopa tariro itsva kuvarwere vekune dzimwe nyika. Dhipatimendi redu rePasirose rinopa varwere vekune dzimwe nyika:
1. **Kubvunzana nenyanzvi dzakasiyana-siyana:** Kuongororwa kwezvirwere uye kugadzirwa kwezvirongwa zvemunhu oga nechikwata chenyanzvi dzinotungamira muchikamu chegomarara remazamu.
2. **Kuwana Mishonga Itsva:** Kuwana mishonga mitsva yekurwisa kenza yakatenderwa neChina panguva yakakodzera, kusanganisira Bireociclib.
3. **Basa Rinoenderera Mberi:** Rubatsiro rwekurapa rwunongoerekana rwaitika, kubva pakubvunzana kwekutanga uye kuita chirongwa chekurapa kusvika pakuteverwa kwenguva refu.
4. **Rubatsiro rweMutauro neKutakura:** Shanduro yehunyanzvi yezvekurapa uye mukana wakatsaurirwa wevarwere vekune dzimwe nyika kugadzirisa matambudziko ezvekufambisa.
**Tibatei Izvozvi**
Kana iwe kana nhengo dzemhuri yako muchirwara nekenza yemazamu yakakwira yeHR+/HER2 uye muchida kuziva kana Bireociclib ingave sarudzo yakakodzera yekurapa, ndapota taurai neInternational Department yeBeijing South Region Oncology Hospital nekukasika. Chikwata chedu chehunyanzvi chichakupai mazano akadzama ekurapa uye rubatsiro rwekutsvaga rubatsiro rwekurapwa muChina.
- ��� Nhare: 400-880-3716
- ��� WeChat: 17801183037
- ��� Email: 100085_010@163.com or myimmnet@163.com
Nguva yekutumira: Kurume-06-2026